Managing recent-onset diabetes: Choosing durable, well-tolerated therapies and understanding the role of incretin-based therapies

Journal of the American Osteopathic Association

Volumn 114, Issue 5 SUPPL. 2, 2014, Pages

  Shubrook Jr , Jay H ^a  

^a OHIO UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84900843447     PISSN: 00986151     EISSN: 19451997     Source Type: Journal    
DOI: 10.7556/jaoa.2014.088     Document Type: Article

References (36)

1. National Diabetes Fact Sheet. Centers for Disease Control and Prevention web site. 2011. http://www.cdc.gov/diabetes/pubs/factsheet11.htm. Accessed January 30, 2014.
2. Dornhorst A, Merrin PK. Primary, secondary and tertiary prevention of non-insulin-dependent diabetes. Postgrad Med J. 1994;70(826):529-535.
3. Sherwin RS, Anderson RM, Buse JB, et al; American Diabetes Association; National Institute of Diabetes and Digestive and Kidney Diseases. Prevention or delay of type 2 diabetes. Diabetes Care. 2004;27 suppl 1:S47-S54.
4. Defronzo RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus [Banting Lecture]. Diabetes. 2009;58(4):773-795. doi:10.2337/db09-9028.
5. Donath MY, Ehses JA, Maedler K, et al. Mechanisms of β-cell death in type 2 diabetes. Diabetes. 2005;54(suppl 2):S108-S113.
6. Kahn SE, Haffner SM, Heise MA, et al; β Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355(23):2427-2443.
7. Wright EE Jr, Stonehouse AH, Cuddihy RM. In support of an early polypharmacy approach to the treatment of type 2 diabetes. Diabetes Obes Metab. 2010;12(11):929-940. doi:10.1111/j.1463-1326.2010.01255.x.
8. Fong DS, Aiello L, Gardner TW, et al; American Diabetes Association. Retinopathy in diabetes. Diabetes Care. 2004;27 suppl 1:S84-S87.
9. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405-412.
10. Chalmers J, Cooper ME. UKPDS and the legacy effect. N Engl J Med. 2008;359(15):1618-1620. doi:10.1056/NEJMe0807625.
11. Murray P, Chune GW, Raghavan VA. Legacy effects from DCCT and UKPDS: what they mean and implications for future diabetes trials. Curr Atheroscler Rep. 2010;12(6):432-439. doi:10.1007/s11883-010-0128-1.
12. Brown JB, Conner C, Nichols GA. Secondary failure of metformin monotherapy in clinical practice [published online December 26, 2009]. Diabetes Care. Mar 2010;33(3):501-506. doi:10.2337/dc09-1749.
13. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach-position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) [published online April 19, 2012] [published correction appears in Diabetes Care. 2013;36(2):490]. Diabetes Care. 2012;35(6):1364-1379. doi:10.2337/dc12-0413.
14. Garber AJ, Abrahamson MJ, Barzilay JI, et al. American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement-executive summary. Endocr Pract. 2013;19(3):536-557. doi:10.4158/EP13176.CS.
15. American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care. 2014;37 suppl 1:S14-S80. doi:10.2337/dc14-S014.
16. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes [published online October 22, 2008]. Diabetes Care. 2009;32(1):193-203. doi:10.2337/dc08-9025.
17. Raskin P. Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitus. Diabetes Metab Res Rev. 2013;29(5): 347-356. doi:10.1002/dmrr.2403.
18. Garcia-Pérez LE, Alvarez M, Dilla T, Gil-Guillén V, Orozco-Beltrán D. Adherence to therapies in patients with type 2 diabetes [published online August 30, 2013]. Diabetes Ther. 2013;4(2): 175-194. doi:10.1007/s13300-013-0034-y.
19. Cernea S. The role of incretin therapy at different stages of diabetes [published online November 10, 2011]. Rev Diabet Stud. 2011;8(3):323-338. doi:10.1900/RDS.2011.8.323.
20. Vilsboll T, Garber AJ. Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic beneft: focus on liraglutide. Diabetes Obes Metab. 2012;14 suppl 2:41-49. doi:10.1111/j.1463-1326.2012.01579.x.
21. Garber AJ. Incretin effects on β-cell function, replication, and mass: the human perspective. Diabetes Care. 2011;34 suppl 2:S258-S263. doi: 10.2337/dc11-s230.
22. Aschner P, Katzeff HL, Guo H, et al; Sitagliptin Study 049 Group. Effcacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes [published online November 25, 2009]. Diabetes Obes Metab. 2010;12(3):252-261. doi:10.1111/j.1463-1326.2009.01187.x.
23. Aschner P, Kipnes MS, Lunceford JK, et al; Sitagliptin Study 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006;29(12):2632-2637.
24. Nonaka K, Kakikawa T, Sato A, et al. Effcacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract. 2008;79(2):291-298.
25. Raz I, Hanefeld M, Xu L, et al; Sitagliptin Study 023 Group. Effcacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia. 2006;49(11):2564-2571.
26. Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes [published online March 18, 2008]. Diabetes Obes Metab. 2008;10(5): 376-386. doi:10.1111/j.1463-1326.2008.00876.x.
27. Rosenstock J, Aguilar-Salinas C, Klein E, Nepal S, List J, Chen R; CV181-011 Study Investigators. Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Curr Med Res Opin. 2009;25(10):2401-2411. doi:10.1185/03007990903178735.
28. Russell-Jones D, Cuddihy RM, Hanefeld M, et al; DURATION-4 Study Group. Effcacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study [published online December 30, 2011]. Diabetes Care. 2012;35(2):252-258. doi:10.2337/dc11-1107.
29. Moretto TJ, Milton DR, Ridge TD, et al. Effcacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study [published correction appears in Clin Ther. 2008;30(10):1937]. Clin Ther. 2008;30(8):1448-1460. doi:10.1016/j.clinthera.2008.08.006.
30. Yuan GH, Song WL, Huang YY, Guo XH, Gao Y. Effcacy and tolerability of exenatide monotherapy in obese patients with newly diagnosed type 2 diabetes: a randomized, 26 weeks metformin-controlled parallel-group study. Chin Med J (Engl). 2012; 125(15): 2677-2681.
31. Vilsboll T, Zdravkovic M, Le-Thi T, et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy signifcantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care. 2007;30(6): 1608-1610.
32. Garber A, Henry R, Ratner R, et al; LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial [published September 24, 2008]. Lancet. 2009;373(9662):473-481. doi:10.1016/S0140-6736(08)61246-5.
33. Jendle J, Nauck MA, Matthews DR, et al; LEAD-2 and LEAD-3 Study Groups. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab. 2009;11(12):1163-1172. doi: 10.1111/j.1463-1326.2009.01158.x.
34. Seino Y, Rasmussen MF, Nishida T Kaku K. Effcacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes. Curr Med Res Opin. 2010;26(5):1013-1022. doi:10.1185/03007991003672551.
35. Bode BW, Testa MA, Magwire M, et al; LEAD-3 Study Group. Patient-re ported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes. Diabetes Obes Metab. 2010;12(7):604-612. doi:10.1111/j.1463-1326.2010.01196.x.
36. Garber A, Henry RR, Ratner R, Hale P, Chang CT, Bode B; LEAD-3 (Mono) Study Group. Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements i n glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes Obes Metab. 2011;13(4):348-356. doi:10.1111/j.1463-1326.2010.01356.x.